A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Inclusion Criteria: * Voluntary agreement to provide written informed consent. * Male or female, Age ≥ 18 years. * Predicted survival ≥ 12 weeks. * Histologically confirmed diagnosis of muscle invasive bladder cancer (MIBC) .Naive of antitumor systematic treatment or radiotherapy. * Have clinically non-metastatic bladder cancer (cT2-T4a, N0-1, M0) determined by imaging. * Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND). * HER2 expressing (i.e. IHC 1+ 2+ or 3+) as confirmed by the local lab. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment. * Male and female participants are eligible to participate if they agree to the contraception use as per study protocol. * Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol. Exclusion Criteria: * Has received other antitumor therapy before planned start of trial treatment. * History of major surgery within 4 weeks of planned start of trial treatment. * Diagnosed with HBsAg, HBcAb positive and HBV DNA copy positive, or HCVAb positive, or HIVAb positive. * Has received a live virus vaccine within 4 weeks of planned start of trial treatment. * NYHA Class III heart failure. * Suffering from active infection requiring systemic treatment. * Uncontrolled hypertension, diabetes, Interstitial lung Disease,…